Gleason score, age and screening: Modeling dedifferentiation in prostate cancer

International Journal of Cancer

Volumn 119, Issue 10, 2006, Pages 2366-2371

  Draisma, Gerrit ^a,b   Postma, Renske ^a   Schröder, Fritz H ^a   Van Der Kwast, Theo H ^a   De Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

Aging; Computer simulation; Gleason score; Prostatic neoplasms; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AGING; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SCREENING; CANCER STAGING; CELL DIFFERENTIATION; COMPUTER SIMULATION; DISEASE COURSE; EARLY DIAGNOSIS; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AGE DISTRIBUTION; AGED; DISEASE PROGRESSION; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX;

EID: 33749647333     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22158     Document Type: Article

References (29)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-14.
2. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
3. Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schroder FH. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst 2001;93:1153-8.
4. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100:1397-405.
5. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-19.
6. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
7. Epstein JI, Walsh PC, Carter HB. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 2001;166:1688-91.
8. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA, Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
9. Crawford ED. Epidemiology of prostate cancer. Urology 2003;62:3-12.
10. Alibhai SM, Krahn MD, Fleshner NE, Cohen MM, Tomlinson GA, Naglie G. The association between patient age and prostate cancer stage and grade at diagnosis. BJU Int 2004;94:303-6.
11. Borek D, Butcher D, Hassanein K, Holmes F. Relationship of age to histologic grade in prostate cancer. Prostate 1990;16:305-11.
12. Beemsterboer PM, Kranse R, de Koning HJ, Habbema JD, Schröder FH. Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Int J Cancer 1999;84:437-41.
13. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-8.
14. Epstein JI. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol 2000;24:477,478.
15. International Union against Cancer (UICC). TNM classification of malignant tumours, 4th edn. Berlin: Springer-Verlag, 1992.
16. Visser O, Coebergh JWW, Schouten LJ. Incidence of cancer in the Netherlands, 1991. Netherlands Cancer Registry, 1994.
17. Spapen SJ, Damhuis RA, Kirkels WJ. Trends in the curative treatment of localized prostate cancer after the introduction of prostate-specific antigen: data from the Rotterdam Cancer Registry. BJU Int 2000;85:474-80.
18. Cullagh PM. Regression models for ordinal data. J R Stat Soc B Stat Methodol 1980;42:109-42.
19. Pierce GB, Speers WC. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988;48:1996-2004.
20. Cheng L, Slezak J, Bergstralh EJ, Cheville JC, Sweat S, Zincke H, Bostwick DG. Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer 1999;86:657-63.
21. Brawn PN, Speights VO. The dedifferentiation of metastatic prostate carcinoma. Br J Cancer 1989;59:85-8.
22. Brawn PN. The dedifferentiation of prostate carcinoma. Cancer 1983;52:246-51.
23. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, Fair WR, Reuter VE. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994;18:979-91.
24. Cumming J, Hacking N, Fairhurst J, Ackery D, Jenkins JD. Distribution of bony metastases in prostatic carcinoma. Br J Urol 1990;66:411-14.
25. Wheeler JA, Zagars GK, Ayala AG. Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression. Cancer 1993;71:3783-7.
26. Adolfsson J, Tribukait B. Evaluation of tumor progression by repeated fine needle biopsies in prostate adenocarcinoma: modal deoxyribonucleic acid value and cytological differentiation. J Urol 1990;144:1408-10.
27. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
28. Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, Partin AW, Veltri RW. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003;170:2274-8.
29. De Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002;98:268-73.